FibroGen Inc (MEX:FGEN)
MXN 6.4 -0.01 (-0.16%) Market Cap: 598.78 Mil Enterprise Value: 711.97 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 44/100

FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 03:00PM GMT
Release Date Price: MXN927
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. My name is Jason Gerberry. I cover smid-cap biotech and especially pharmaceutical for Bank of America. I'm pleased to be introducing our next company presenter, FibroGen and new CEO, Enrique Conterno. FibroGen is -- most would know the company for its development of roxadustat for anemia associated with dialysis or renal disease, but the company also has an emerging early to mid-stage pipeline with pamrevlumab for fibrotic disorders.

So Enrique, first off, thanks for joining us at the conference on a virtual basis.

Enrique A. Conterno
FibroGen, Inc. - CEO & Director

No, thank you, Jason. It's a pleasure for me to be here and talk about the progress we're making at FibroGen.

Questions & Answers

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Great. I mean, look, you're no longer new to the role, but I imagine that the opportunity with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot